S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|ONO and Gilead Announce Exclusive License Agreement to Develop BTK Inhibitor, ONO-4059, for the Treatment of B-cell Malignancies and Other Diseases|
|Study Comparing Opdivo (nivolumab) to Chemotherapy in Treatment Naïve Advanced Melanoma Patients Marks First PD-1 Immune Checkpoint Inhibitor to Demonstrate a Survival Benefit in a Phase 3 Trial|
|Phase 2 Objective Response Rate and Survival Data for Opdivo (nivolumab) in Heavily Pre-treated Advanced Squamous Cell Non-Small Cell Lung Cancer to be Presented at the 2014 Chicago Multidisciplinary Symposium on Thoracic Oncology|
|New International GPCR Consortium Formed with Pharma and Academia to Advance Structural Information about G-protein Coupled Receptors (2014/10/28)|
|Receptos Provides Development Updates and Reports Third Quarter 2014 Financial Results|
Click above to view more mutual fund data and stats for ophly - ONO Pharmaceutical Co., Ltd. ADR.